A phase 1 study of intravenous mitazalimab, a CD40 agonistic monoclonal antibody, in patients with advanced solid tumors-Reference-Cited by-同舟云学术

A phase 1 study of intravenous mitazalimab, a CD40 agonistic monoclonal antibody, in patients with advanced solid tumors

Published:2022-12-20 Issue:1 Volume:41 Page:93-104
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Moreno Victor,Perets Ruth,Peretz-Yablonski Tamar,Fourneau Nele,Girgis Suzette,Guo Yue,Hellemans Peter,Verona Raluca,Pendás Natalia,Xia Qi,Geva Ravit,Calvo Emiliano

Funder

Janssen Research and Development

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s10637-022-01319-2.pdf

Reference27 articles.

1. Vonderheide RH (2007) Prospect of targeting the CD40 pathway for cancer therapy. Clin Cancer Res 13(4):1083–1088. https://doi.org/10.1158/1078-0432.CCR-06-1893

2. Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, Noelle RJ (2009) Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev 229(1):152–172. https://doi.org/10.1111/j.1600-065X.2009.00782.x

3. Eliopoulos AG, Young LS (2004) The role of the CD40 pathway in the pathogenesis and treatment of cancer. Curr Opin Pharmacol 4(4):360–367. https://doi.org/10.1016/j.coph.2004.02.008

4. Ma DY, Clark EA (2009) The role of CD40 and CD154/CD40L in dendritic cells. Semin Immunol 21(5):265–272. https://doi.org/10.1016/j.smim.2009.05.010

5. Zarnegar B, He JQ, Oganesyan G, Hoffmann A, Baltimore D, Cheng G (2004) Unique CD40-mediated biological program in B cell activation requires both type 1 and type 2 NF-kappaB activation pathways. Proc Natl Acad Sci U S A 101(21):8108–8113. https://doi.org/10.1073/pnas.0402629101

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug combinations of camptothecin derivatives promote the antitumor properties;European Journal of Medicinal Chemistry;2024-09

2. Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study;The Lancet Oncology;2024-07

3. Next-generation CD40 agonists for cancer immunotherapy;Expert Opinion on Biological Therapy;2024-05-03

4. Evaluation of a Combinatorial Immunotherapy Regimen That Can Cure Mice Bearing MYCN-Driven High-Risk Neuroblastoma That Resists Current Clinical Therapy;Journal of Clinical Medicine;2024-04-26

5. Engaging stimulatory immune checkpoint interactions in the tumour immune microenvironment of primary liver cancers – how to push the gas after having released the brake;Frontiers in Immunology;2024-02-19